MS
BIOA

Maven Securities’s BioAge Labs BIOA Stock Holding History

Maven Securities’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,000
Closed -$520K – 1048
2024
Q3 		$520K Buy
+25,000
New +$501K 0.01% 640

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maven Securities's BIOA Position: Q4 2024 in Review

Maven Securities sold out of BioAge Labs (BIOA) in Q4 2024, closing a stake of 25,000 shares — an estimated $520K sold.

Maven Securities first reported a position in BIOA in Q3 2024 and held it in 1 quarter. The position peaked at $520K in Q3 2024. 65 funds tracked by Wall St. Rank hold BIOA as of Q4 2024.

  • Maven Securities reported no remaining BioAge Labs position as of Q4 2024 after selling out during the quarter.
  • Maven Securities sold 25,000 BioAge Labs shares in Q4 2024, an estimated $520K.
  • Maven Securities first reported a position in BioAge Labs in Q3 2024 and held it in 1 quarter.
  • Maven Securities's BioAge Labs position peaked at $520K in Q3 2024.
  • 65 funds tracked by Wall St. Rank held BioAge Labs as of Q4 2024.

Based on Maven Securities's 13F filing for Q4 2024, filed 14 Feb 2025.